Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.44 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.44 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 7/20 | 0.44 |
| ▸ | CA2 | P00918 | 7/20 | 0.44 |
| ▸ | CA9 | Q16790 | 5/20 | 0.44 |
| ▸ | CA12 | O43570 | 4/20 | 0.44 |
| ▸ | CA7 | P43166 | 4/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.44 |
| ▸ | MGLL | Q99685 | 2/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.37 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.37 |
| ▸ | HPGD | P15428 | 4/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.35 |
| ▸ | RECQL | P46063 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15306049 | 1.00 | TAS1R3 (0.44) | TAS1R3TAS1R1TAS1R2CA1CA2 | |
| SCHEMBL9904526 | 1.00 | TAS1R3 (0.44) | TAS1R3TAS1R1TAS1R2CA1CA2 | |
| SCHEMBL9900931 | 0.72 | CA1 (0.47) | TAS1R3TAS1R1TAS1R2CA1CA2 | |
| SCHEMBL9924095 | 0.72 | CA1 (0.47) | TAS1R3TAS1R1TAS1R2CA1CA2 | |
| SCHEMBL9900764 | 0.70 | THRB (0.52) | TAS1R3TAS1R1TAS1R2CA1CA2 | |
| SCHEMBL9904888 | 0.70 | THRB (0.52) | TAS1R3TAS1R1TAS1R2CA1CA2 | |
| SCHEMBL10050934 | 0.68 | POLB (0.51) | MGLLGABRA1HPGDALDH1A1TDP1 | |
| SCHEMBL266382 | 0.68 | POLB (0.51) | MGLLGABRA1HPGDALDH1A1TDP1 | |
| SCHEMBL9901144 | 0.68 | CA1 (0.57) | TAS1R3TAS1R1TAS1R2CA1CA2 | |
| SCHEMBL10041973 | 0.68 | POLB (0.51) | MGLLGABRA1HPGDALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11583527-B2 | Hydantoin derivatives useful as Kv3 inhibitors | AUTIFONY THERAPEUTICS LIMITED (GB) | 2023-02-21 | — | — | US | disclosed |
| US-20220054490-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | AUTIFONY THERAPEUTICS LIMITED (GB) | 2022-02-24 | — | — | US | disclosed |
| US-11197859-B2 | Hydantoin derivatives useful as Kv3 inhibitors | AUTIFONY THERAPEUTICS LIMITED (GB) | 2021-12-14 | — | — | US | disclosed |
| US-20200360379-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | GLAXOSMITHKLINE S.P.A. (IT) | 2020-11-19 | — | — | US | disclosed |
| US-20190192516-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | GLAXOSMITHKLINE S.P.A. (IT) | 2019-06-27 | — | — | US | disclosed |
| US-10265316-B2 | Hydantoin derivatives useful as Kv3 inhibitors | AUTIFONY THERAPEUCTICS LIMITED (GB) | 2019-04-23 | — | — | US | disclosed |
| US-20170273981-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | GLAXOSMITHKLINE S.P.A. (IT) | 2017-09-28 | — | — | US | disclosed |
| US-20160251340-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | GLAXOSMITHKLINE S.P.A. (IT) | 2016-09-01 | — | — | US | disclosed |
| US-9346790-B2 | Hydantoin derivatives useful as Kv3 inhibitors | AUTIFONY THERAPEUTICS LIMITED (GB) | 2016-05-24 | — | — | US | disclosed |
| EP-2649066-B1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | AUTIFONY THERAPEUTICS LTD (GB) | 2015-10-21 | — | — | EP | disclosed |
| EP-2649066-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | Autifony Therapeutics Limited (GB) | 2013-10-16 | — | — | EP | disclosed |
| US-20130267510-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | AUTIFONY THERAPEUTICS LIMITED (GB) | 2013-10-10 | — | — | US | disclosed |
| WO-2012076877-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | AUTIFONY THERAPEUTICS LIMITED (GB) | 2012-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190192516-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | KCNN3, KCND3, KCNA3 | TAS1R3 612/4885TAS1R1 2185/4885TAS1R2 2202/4885 |
| US-20160251340-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | KCNA3, KCND3, KCNN3 | TAS1R3 471/4885TAS1R1 1733/4885TAS1R2 1877/4885 |
| US-11583527-B2 | Hydantoin derivatives useful as Kv3 inhibitors | KCNN3, KCND3, KCNA3 | TAS1R3 612/4885TAS1R1 2185/4885TAS1R2 2202/4885 |
| US-20220054490-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | KCNN3, KCND3, KCNA3 | TAS1R3 612/4885TAS1R1 2185/4885TAS1R2 2202/4885 |
| US-20200360379-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | KCNN3, KCND3, KCNA3 | TAS1R3 612/4885TAS1R1 2185/4885TAS1R2 2202/4885 |
| US-20170273981-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | KCNA3, KCND3, KCNN3 | TAS1R3 471/4885TAS1R1 1733/4885TAS1R2 1877/4885 |
| US-10265316-B2 | Hydantoin derivatives useful as Kv3 inhibitors | KCNA3, KCND3, KCNN3 | TAS1R3 471/4885TAS1R1 1733/4885TAS1R2 1877/4885 |
| US-20130267510-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | KCNA3, KCND3, KCNN3 | TAS1R3 471/4885TAS1R1 1733/4885TAS1R2 1877/4885 |
| US-11197859-B2 | Hydantoin derivatives useful as Kv3 inhibitors | KCNN3, KCND3, KCNA3 | TAS1R3 612/4885TAS1R1 2185/4885TAS1R2 2202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.